Cost-Effectiveness of Nivolumab plus Ipilimumab in LATAM's Renal Cell Carcinoma Market
This article analyzes the economic viability of Nivolumab plus Ipilimumab for Renal Cell Carcinoma, highlighting its impact on LATAM's healthcare landscape.
Quick Answer
This article analyzes the economic viability of Nivolumab plus Ipilimumab for Renal Cell Carcinoma, highlighting its impact on LATAM's healthcare landscape.
Key Questions
- Why is the ICER negative for nivolumab plus ipilimumab, and what does this mean clinically?
- How do the per-patient savings of $41,864 translate to real-world healthcare affordability?
- Is this cost-effectiveness analysis applicable to other LATAM countries beyond Uruguay?
- What clinical trial data support the efficacy claims in this cost-effectiveness analysis?
- How do ANVISA and other LATAM regulators use health economic evidence in reimbursement decisions?
A pharmacoeconomic analysis in Uruguay found nivolumab plus ipilimumab delivers mean per-patient savings of $41,864 compared with pembrolizumab plus axitinib for advanced renal cell carcinoma. The combination showed a negative incremental cost-effectiveness ratio (ICER) of -$74,266 per quality-adjusted life year (QALY), indicating it is both less costly and more effective than the comparator regimen.
Contents9 sections
Key Takeaways
- Cost advantage: Nivolumab plus ipilimumab demonstrates mean per-patient savings of $41,864 versus pembrolizumab plus axitinib in intermediate- and poor-risk advanced renal cell carcinoma, per a Uruguayan pharmacoeconomic analysis.
- Negative ICER: The combination achieved a negative ICER of -$74,266 per QALY, indicating a "dominant" strategy that costs less while delivering superior clinical outcomes.
- Budget impact: A five-year model projects $21.7 million in reduced high-cost drug expenditure for the Uruguayan healthcare system.
- Clinical foundation: Efficacy data derive from CheckMate 214 (nivolumab plus ipilimumab) and KEYNOTE-426 (pembrolizumab plus axitinib). See LATAM regulatory pathways for context.
- Regulatory status: Both combinations hold FDA approval for first-line advanced renal cell carcinoma, with nivolumab plus ipilimumab specifically indicated for intermediate- and poor-risk patients.
What Is Nivolumab plus Ipilimumab?
Nivolumab (Opdivo) and ipilimumab (Yervoy) are monoclonal antibodies that function as immune checkpoint inhibitors. Nivolumab targets programmed death receptor-1 (PD-1). Ipilimumab targets cytotoxic T-lymphocyte-associated protein 4 (CTLA-4).
The combination is indicated for first-line treatment of advanced renal cell carcinoma (RCC) in patients with intermediate or poor prognostic risk. This dual-checkpoint approach enhances T-cell activation and proliferation, enabling improved tumor recognition.
The FDA approved this combination for RCC in April 2018 based on results from the CheckMate 214 trial. The regimen demonstrated superior overall survival versus sunitinib in intermediate- and poor-risk patients.
What Did the Uruguayan Cost-Effectiveness Analysis Find?
The pharmacoeconomic analysis compared nivolumab plus ipilimumab with pembrolizumab plus axitinib in the Uruguayan healthcare context. The study used health economic modeling to evaluate cost-effectiveness and budget impact.
Key findings include:
- Per-patient savings: Mean savings of $41,864 per patient with nivolumab plus ipilimumab versus pembrolizumab plus axitinib.
- Incremental cost-effectiveness ratio: ICER of -$74,266 per QALY indicates the regimen is both cost-saving and more effective.
- Five-year budget impact: Projected reduction of $21.7 million in high-cost drug expenditure over five years in Uruguay.
The negative ICER represents a "dominant" strategy in health economics. The intervention costs less and delivers greater health benefit compared with the comparator.
What Clinical Evidence Supports These Regimens?
The cost-effectiveness modeling incorporates efficacy data from pivotal phase 3 trials.
CheckMate 214 (NCT02231749): This trial randomized 1,096 patients with advanced RCC to nivolumab plus ipilimumab versus sunitinib. In intermediate- and poor-risk patients, the combination demonstrated superior overall survival. With 8 years of median follow-up, the hazard ratio for overall survival was 0.69 (95% CI: 0.59–0.81) in this population.
KEYNOTE-426 (NCT02853331): This trial randomized 861 patients to pembrolizumab plus axitinib versus sunitinib. The combination showed statistically significant improvement in overall survival (HR 0.53; 95% CI: 0.38–0.74; p<0.0001) and progression-free survival.
The FDA approved pembrolizumab plus axitinib in April 2019 based on KEYNOTE-426 results.
How Does This Impact LATAM Healthcare Systems?
The cost-effectiveness analysis carries significant implications for Latin American healthcare systems facing budget constraints.
Payer decision-making: The negative ICER and substantial per-patient savings provide health economic justification for formulary placement. Payers can prioritize nivolumab plus ipilimumab based on demonstrated cost advantage.
Patient access: Intermediate- and poor-risk advanced RCC patients represent a defined population eligible for first-line immunotherapy. Cost savings may expand access in resource-constrained systems.
Budget sustainability: The projected $21.7 million five-year budget reduction addresses healthcare affordability concerns in markets with limited oncology drug budgets.
What Is the Regulatory Context in LATAM?
Nivolumab and ipilimumab hold approved immunotherapy pathways across multiple jurisdictions. This includes the U.S. Food and Drug Administration, European Medicines Agency, and Brazilian Health Regulatory Agency (ANVISA).
The pharmacoeconomic analysis was conducted to inform reimbursement and formulary decisions within the Uruguayan healthcare system. Health economic evidence supports market access discussions with payers and national health authorities in LATAM.
ANVISA and other regional regulatory bodies increasingly incorporate health economic data into market access frameworks. Economic evidence complements clinical efficacy and safety data in reimbursement assessments.
What Are the Limitations of This Analysis?
The Uruguayan analysis provides a single-market benchmark. Applicability to other LATAM markets depends on local factors:
- Healthcare infrastructure and delivery models
- Drug pricing and negotiation practices
- Patient population characteristics
- Payer budget constraints and priorities
Brazil, Mexico, and Argentina may have different economic profiles. The demonstrated cost advantage suggests potential relevance across LATAM, warranting region-specific economic evaluations.
Safety data specific to this pharmacoeconomic analysis were not reported. Clinicians should refer to established product labeling and published clinical trial data for comprehensive safety profiles.
Frequently Asked Questions
Why is the ICER negative for nivolumab plus ipilimumab, and what does this mean clinically?
A negative ICER of -$74,266 per QALY indicates that nivolumab plus ipilimumab is both more cost-effective and clinically superior to pembrolizumab plus axitinib in the Uruguayan analysis. Negative ICERs represent dominant strategies in health economics—the intervention costs less and delivers greater health benefit.
How do the per-patient savings of $41,864 translate to real-world healthcare affordability?
Mean per-patient savings of $41,864 represent the average cost difference over a treatment course. For Uruguay's healthcare system, this translates to reduced public payer expenditure per treated patient and improved budget allocation for other oncology priorities. The $21.7 million five-year budget reduction illustrates cumulative system-level impact.
Is this cost-effectiveness analysis applicable to other LATAM countries beyond Uruguay?
The Uruguayan analysis provides a benchmark, but applicability to other LATAM markets depends on local factors: healthcare infrastructure, drug pricing and negotiation practices, patient population characteristics, and payer budget constraints. Brazil, Mexico, and Argentina may have different economic profiles.
What clinical trial data support the efficacy claims in this cost-effectiveness analysis?
The cost-effectiveness modeling incorporates efficacy data from CheckMate 214 (NCT02231749) for nivolumab plus ipilimumab and KEYNOTE-426 (NCT02853331) for pembrolizumab plus axitinib. CheckMate 214 demonstrated superior overall survival versus sunitinib in intermediate/poor-risk patients.
How do ANVISA and other LATAM regulators use health economic evidence in reimbursement decisions?
ANVISA and other regional regulatory agencies increasingly incorporate health economic data into market access and reimbursement assessments. Economic evidence complements clinical efficacy and safety data, supporting payer negotiations and formulary decisions across LATAM countries.
Primary Sources
- ClinicalTrials.gov — NCT02231749: CheckMate 214 trial of nivolumab plus ipilimumab versus sunitinib in advanced renal cell carcinoma
- ClinicalTrials.gov — NCT02853331: KEYNOTE-426 trial of pembrolizumab plus axitinib versus sunitinib in renal cell carcinoma
- FDA — FDA approves pembrolizumab plus axitinib for advanced renal cell carcinoma (April 19, 2019)
- FDA — YERVOY (ipilimumab) Prescribing Information (revised May 2025)
- Pharmacoeconomic analysis of nivolumab plus ipilimumab versus pembrolizumab plus axitinib in advanced renal cell carcinoma: Uruguayan healthcare system perspective. Cost-effectiveness and five-year budget impact model, 2024–2025.
Continue Exploring
Jump into the entities behind this story.
This article follows our editorial standards. Report a correction via editorial contact.
Continue Your Research
Industry Reports & Whitepapers
- La Negoziazione del Prezzo dei Farmaci Oncologici in Italia — This whitepaper analyzes the market benchmark role in negotiating oncology drug prices in Italy, hig…
- Cytological Specimens in the Molecular Era of Metastatic Melanoma — This whitepaper discusses the role of cytological specimens in diagnosing metastatic melanoma and th…